Literature DB >> 22851180

Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.

Arati Khanna-Gupta1, Nirmalee Abayasekara, Michelle Levine, Hong Sun, Maria Virgilio, Navid Nia, Stephanie Halene, Paolo Sportoletti, Jee-Yeong Jeong, Pier Paolo Pandolfi, Nancy Berliner.   

Abstract

NPM1 is a ubiquitously expressed nucleolar phosphoprotein, the gene for which maps to chromosome 5q35 in close proximity to a commonly deleted region associated with (del)5q, a type of myelodysplastic syndrome (MDS). This region is also a frequent target of deletions in de novo and therapy-related MDS/acute myeloid leukemia. Previous studies have shown that Npm1(+/-) mice develop an MDS-like disease that transforms to acute myeloid leukemia over time. To better understand the mechanism by which NPM1 haploinsufficiency causes an MDS phenotype, we generated factor-dependent myeloid cell lines from the bone marrow of Npm1(+/+) and Npm1(+/-) mice and demonstrated compromised neutrophil-specific gene expression in the MNPM1(+/-) cells. We attribute these observations to increased levels of the shorter, dominant negative leukemogenic isoform (p30) of CCAAT enhancer-binding protein α (C/EBPα). We show that this increase is caused, in part, by elevated levels of the activated translation initiation factor eIF4E, overexpression of which also increases translation of C/EBPαp30 in HEK293 cells. In a positive feedback loop, eIF4E expression is further elevated both at the mRNA and protein levels by C/EBPαp30 but not by the full-length C/EBPαp42. Re-expression of C/EBPαp42 or NPM1 but not C/EBPαp30 in MNPM1(+/-) cells partially rescues the myeloid phenotype. Our observations suggest that the aberrant feed-forward pathway that keeps eIF4E and C/EBPαp30 elevated in NPM1(+/-) cells contributes to the MDS phenotype associated with NPM1 deficiency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851180      PMCID: PMC3463350          DOI: 10.1074/jbc.M112.373274

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Phosphorylation of mammalian eIF4E by Mnk1 and Mnk2: tantalizing prospects for a role in translation.

Authors:  M Mahalingam; J A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2001

Review 2.  Regulation and deregulation of mRNA translation during myeloid maturation.

Authors:  Arati Khanna-Gupta
Journal:  Exp Hematol       Date:  2010-11-18       Impact factor: 3.084

3.  c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.

Authors:  Chen-Ju Lin; Regina Cencic; John R Mills; Francis Robert; Jerry Pelletier
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

4.  Role of nucleophosmin in embryonic development and tumorigenesis.

Authors:  Silvia Grisendi; Rosa Bernardi; Marco Rossi; Ke Cheng; Luipa Khandker; Katia Manova; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

Review 5.  Does the ribosome translate cancer?

Authors:  Davide Ruggero; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

Review 6.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 7.  Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha).

Authors:  Arati Khanna-Gupta
Journal:  Blood Cells Mol Dis       Date:  2008-04-10       Impact factor: 3.039

8.  Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation.

Authors:  Zhaoliang Li; David Boone; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

9.  Nucleophosmin regulates the stability and transcriptional activity of p53.

Authors:  Emanuela Colombo; Jean-Christophe Marine; Davide Danovi; Brunangelo Falini; Pier Giuseppe Pelicci
Journal:  Nat Cell Biol       Date:  2002-07       Impact factor: 28.824

10.  Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.

Authors:  Peggy Kirstetter; Mikkel B Schuster; Oksana Bereshchenko; Susan Moore; Heidi Dvinge; Elke Kurz; Kim Theilgaard-Mönch; Robert Månsson; Thomas A Pedersen; Thomas Pabst; Evelin Schrock; Bo T Porse; Sten Eirik W Jacobsen; Paul Bertone; Daniel G Tenen; Claus Nerlov
Journal:  Cancer Cell       Date:  2008-04       Impact factor: 31.743

View more
  9 in total

Review 1.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

Review 2.  The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.

Authors:  Michael J Osborne; Katherine L B Borden
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

Review 3.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

Review 4.  Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Authors:  P Sportoletti; E Varasano; R Rossi; A Mupo; E Tiacci; G Vassiliou; M P Martelli; B Falini
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

5.  The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.

Authors:  F Hariri; M Arguello; L Volpon; B Culjkovic-Kraljacic; T H Nielsen; J Hiscott; K K Mann; K L B Borden
Journal:  Leukemia       Date:  2013-03-07       Impact factor: 11.528

6.  Positional proteomics reveals differences in N-terminal proteoform stability.

Authors:  Daria Gawron; Elvis Ndah; Kris Gevaert; Petra Van Damme
Journal:  Mol Syst Biol       Date:  2016-02-18       Impact factor: 11.429

Review 7.  Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.

Authors:  Christos Vaklavas; Scott W Blume; William E Grizzle
Journal:  Front Oncol       Date:  2017-07-26       Impact factor: 6.244

8.  GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations.

Authors:  Paolo Sportoletti; Letizia Celani; Emanuela Varasano; Roberta Rossi; Daniele Sorcini; Chiara Rompietti; Francesca Strozzini; Beatrice Del Papa; Valerio Guarente; Giulio Spinozzi; Debora Cecchini; Oxana Bereshchenko; Torsten Haferlach; Maria Paola Martelli; Franca Falzetti; Brunangelo Falini
Journal:  Leukemia       Date:  2019-02-12       Impact factor: 11.528

Review 9.  Targeting EIF4F complex in non-small cell lung cancer cells.

Authors:  Lu Dai; Zhen Lin; Yueyu Cao; Yihan Chen; Zengguang Xu; Zhiqiang Qin
Journal:  Oncotarget       Date:  2017-06-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.